Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study [0.03%]
基于磁共振成像的前列腺癌患者的主动监测失效预测：一项跨国队列研究
Nikita Sushentsev,Irene G Li,George Xu et al.
Nikita Sushentsev et al.
Background and objective: Magnetic resonance imaging (MRI)-driven active surveillance (AS) is increasingly used for management of prostate cancer (PC). The aim of our study was to determine the oncological safety of conte...
Incidence and Predictors of Acute Kidney Injury and Acute Kidney Disease After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients [0.03%]
机器人辅助根治性前列腺切除术后急性肾损伤和急性肾脏疾病的发生率及预测因素
Paolo Zaurito,Alexandre Calado,Leonardo Quarta et al.
Paolo Zaurito et al.
Background and objective: Acute kidney injury (AKI) and acute kidney disease (AKD) are neglected complications of robot-assisted radical prostatectomy (RARP) that may lead to chronic kidney disease (CKD). We investigated ...
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis [0.03%]
转移性激素敏感性前列腺癌伴脏器转移患者的治疗疗效评估：系统评价和网络 meta 分析
Fabiano Flauto,Giuseppe Neola,Carmine Caso et al.
Fabiano Flauto et al.
Background and objective: Metastatic hormone-sensitive prostate cancer (mHSPC) patients with visceral disease (VD) represent a high-risk subgroup associated with poor prognosis. Despite the introduction of treatment inten...
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial [0.03%]
年轻男性前列腺癌筛查项目中需要对前列腺 grading group 2癌症进行早期检测吗？来自PROBASE筛查试验的结果
Peter Albers,Agne Krilaviciute,Petra Seibold et al.
Peter Albers et al.
In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommende...
The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era [0.03%]
当代积极监测下的临床病理分期I期前列腺癌的自然发展史
Kevin Shee,Jonathan J Song,Janet E Cowan et al.
Kevin Shee et al.
Background and objective: Grade group 1 (GG1, Gleason 3 + 3) prostate cancer (PCa) is considered low risk but can upgrade, and is managed with active surveillance (AS). Amidst recent controversy of whether GG1 PCa should ...
Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies [0.03%]
有关 metastatic castration-resistant prostate cancer 男性患者镭[223Th]氯化物现实世界疗效的系统性文献回顾：来自观察性研究的结果
Michaela Lunan-Taylor,Amit D Raval,Nguyen Thi Nhan Phan et al.
Michaela Lunan-Taylor et al.
Background and objective: Radium-223 (Ra-223) has been approved since 2013 for men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Since then, the treatment landscape has changed dramati...
Re: Gerhardt Attard, Neeraj Agarwal, Julie Graff, et al. Niraparib plus Abiraterone Acetate and Prednisone for HRR-mutated Metastatic Castration-sensitive Prostate Cancer: Results from the AMPLITUDE Phase 3 Trial. J Clin Oncol 2025;43(17 Suppl):LBA5006 [0.03%]
纳拉帕利联合阿比特龙和泼尼松治疗同源重组修复基因突变的转移性雄激素敏感前列腺癌：III期AMPLITUDE试验结果
Giuseppe Di Lorenzo,Francesco Montorsi,Carlo Buonerba
Giuseppe Di Lorenzo
Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go? [0.03%]
肌层浸润性伴原位癌膀胱尿路上皮癌的放射治疗：仍不可行吗？
Constance Huck,Vérane Achard,Jason Efstathiou et al.
Constance Huck et al.
Background and objective: This narrative review explores the impact of carcinoma in situ (CIS) on outcomes in muscle-invasive bladder cancer (MIBC) after trimodal therapy (TMT) comprising transurethral resection of bladde...
Assessment of the Reporting and Incidence of Prostate Cancer Unconventional Histologies in Tertiary Referral Institutions: An Under-reported but Exploding Phenomenon? [0.03%]
三级医疗机构前列腺癌非典型病理报告和发生率的评估：被低估但正在扩大的现象吗？
Giancarlo Marra,Geert J L H van Leenders,Guglielmo David et al.
Giancarlo Marra et al.
Prostate cancer (PCa) with unconventional histologies (UHs) is not infrequent and may be associated with different prognosis compared with conventional PCa depending on the type, subtype, or pattern considered. A recent World Health Organiz...
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes [0.03%]
PERSEUS1：一项开放性、研究者发起的单组II期试验，在错配修复缺陷和其它免疫敏感型分子亚型转移去势抵抗性前列腺癌患者中检验帕博利珠单抗疗效
Pasquale Rescigno,Maria Dolores Fenor de la Maza,Holly Tovey et al.
Pasquale Rescigno et al.
Background and objective: Some metastatic castration-resistant prostate cancers (mCRPCs) present mismatch repair deficiency (MMRd) and other molecular subtypes potentially sensitive to immune checkpoint inhibitors (ICIs)....